Cargando…

Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity

Rhodococcus equi is a facultative intracellular bacterium causing severe pyogranulomatous pneumonia, ulcerative enterocolitis, and mesenteric lymphadenopathy in foals aged less than 6 months. Less frequently, this pathogen affects various other species, such as pigs, cattle, cats, and even humans. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Trevisani, Marcel M., Hanna, Ebert S., Oliveira, Aline F., Cardoso, Silvia A., Roque-Barreira, Maria C., Soares, Sandro G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425581/
https://www.ncbi.nlm.nih.gov/pubmed/28553279
http://dx.doi.org/10.3389/fmicb.2017.00857
_version_ 1783235332263641088
author Trevisani, Marcel M.
Hanna, Ebert S.
Oliveira, Aline F.
Cardoso, Silvia A.
Roque-Barreira, Maria C.
Soares, Sandro G.
author_facet Trevisani, Marcel M.
Hanna, Ebert S.
Oliveira, Aline F.
Cardoso, Silvia A.
Roque-Barreira, Maria C.
Soares, Sandro G.
author_sort Trevisani, Marcel M.
collection PubMed
description Rhodococcus equi is a facultative intracellular bacterium causing severe pyogranulomatous pneumonia, ulcerative enterocolitis, and mesenteric lymphadenopathy in foals aged less than 6 months. Less frequently, this pathogen affects various other species, such as pigs, cattle, cats, and even humans. Although rhodococcosis is treated with a combination of antimicrobial agents, resistance is developed in some cases, and thus, antimicrobial susceptibility must be monitored and managed. Considering these limitations of the current therapy and unavailability of a vaccine to prevent the disease, research is particularly focused on the development of an effective vaccine against rhodococcosis. Most vaccines undergoing development utilize the virulence-associated protein (Vap) A antigen, which was identified previously as a key virulence factor of R. equi. Nevertheless, other proteins, such as VapG, present in most virulent R. equi strains, are also encoded by vap genes located on the R. equi bacterial virulence plasmid. In the present study, we evaluated the effect of VapG immunization on the survival of R. equi-challenged mice. We used attenuated Salmonella as a carrier for VapG (Salmonella-vapG+), a procedure previously adopted to develop a VapA-based vaccine. We observed that vaccination with Salmonella-vapG+ induced both an increased IFN-γ, IL-12, and TNF-α production, and a decreased bacterial burden in organs of the R. equi-challenged mice. Nevertheless, Salmonella-vapG+ vaccination protected only 50% of the mice challenged with a lethal dose of R. equi. Interestingly, we observed an increased frequency of B cells in the spleen of Salmonella-vapG+-vaccinated mice and showed that Salmonella-vapG+-vaccinated R. equi-challenged B-cell-knockout mice did not reduce the bacterial burden. Given these results, we discussed the potential role of the humoral immune response induced by Salmonella-vapG+ vaccination in conferring protection against R. equi infection, as well as the employment of VapG antigen for obtaining hyperimmune plasma to prevent rhodoccocosis in young foals.
format Online
Article
Text
id pubmed-5425581
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54255812017-05-26 Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity Trevisani, Marcel M. Hanna, Ebert S. Oliveira, Aline F. Cardoso, Silvia A. Roque-Barreira, Maria C. Soares, Sandro G. Front Microbiol Microbiology Rhodococcus equi is a facultative intracellular bacterium causing severe pyogranulomatous pneumonia, ulcerative enterocolitis, and mesenteric lymphadenopathy in foals aged less than 6 months. Less frequently, this pathogen affects various other species, such as pigs, cattle, cats, and even humans. Although rhodococcosis is treated with a combination of antimicrobial agents, resistance is developed in some cases, and thus, antimicrobial susceptibility must be monitored and managed. Considering these limitations of the current therapy and unavailability of a vaccine to prevent the disease, research is particularly focused on the development of an effective vaccine against rhodococcosis. Most vaccines undergoing development utilize the virulence-associated protein (Vap) A antigen, which was identified previously as a key virulence factor of R. equi. Nevertheless, other proteins, such as VapG, present in most virulent R. equi strains, are also encoded by vap genes located on the R. equi bacterial virulence plasmid. In the present study, we evaluated the effect of VapG immunization on the survival of R. equi-challenged mice. We used attenuated Salmonella as a carrier for VapG (Salmonella-vapG+), a procedure previously adopted to develop a VapA-based vaccine. We observed that vaccination with Salmonella-vapG+ induced both an increased IFN-γ, IL-12, and TNF-α production, and a decreased bacterial burden in organs of the R. equi-challenged mice. Nevertheless, Salmonella-vapG+ vaccination protected only 50% of the mice challenged with a lethal dose of R. equi. Interestingly, we observed an increased frequency of B cells in the spleen of Salmonella-vapG+-vaccinated mice and showed that Salmonella-vapG+-vaccinated R. equi-challenged B-cell-knockout mice did not reduce the bacterial burden. Given these results, we discussed the potential role of the humoral immune response induced by Salmonella-vapG+ vaccination in conferring protection against R. equi infection, as well as the employment of VapG antigen for obtaining hyperimmune plasma to prevent rhodoccocosis in young foals. Frontiers Media S.A. 2017-05-11 /pmc/articles/PMC5425581/ /pubmed/28553279 http://dx.doi.org/10.3389/fmicb.2017.00857 Text en Copyright © 2017 Trevisani, Hanna, Oliveira, Cardoso, Roque-Barreira and Soares. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Trevisani, Marcel M.
Hanna, Ebert S.
Oliveira, Aline F.
Cardoso, Silvia A.
Roque-Barreira, Maria C.
Soares, Sandro G.
Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title_full Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title_fullStr Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title_full_unstemmed Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title_short Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity
title_sort vaccination of mice with virulence-associated protein g (vapg) antigen confers partial protection against rhodococcus equi infection through induced humoral immunity
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425581/
https://www.ncbi.nlm.nih.gov/pubmed/28553279
http://dx.doi.org/10.3389/fmicb.2017.00857
work_keys_str_mv AT trevisanimarcelm vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity
AT hannaeberts vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity
AT oliveiraalinef vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity
AT cardososilviaa vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity
AT roquebarreiramariac vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity
AT soaressandrog vaccinationofmicewithvirulenceassociatedproteingvapgantigenconferspartialprotectionagainstrhodococcusequiinfectionthroughinducedhumoralimmunity